Search Results
Jun 15, 2026, 08:35 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new two-year data from the Phase 3 CAHtalyst® Pediatric study showing positive growth outcomes in children and adolescents
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 08:30 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new Phase 3 CAHtalyst® Adult study data demonstrating improved cardiometabolic outcomes alongside sustained glucocorticoid
More news about: Neurocrine Biosciences, Inc.
Jun 09, 2026, 08:00 ET Tom Lee's Fundstrat Capital Announces May 2026 Rebalance for Granny Shots US Small- & Mid-Cap ETF
and we keep this timing in mind when we rebalance."May 2026 Rebalance SummaryAdditions: CRDO, DKS, FSLR, MOD, NBIX, NTRA, RMBS, TTMI, ZETA, ZMDeletions: ARRY, AWI, CARR, DCI, H, IBP, ITT, UHSThe rebalance reflects updated positioning across
More news about: Fundstrat Capital
Jun 08, 2026, 16:05 ET Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new post-hoc data from the KINECT® 4 clinical trial demonstrating that adults with tardive dyskinesia (TD) treated with
More news about: Neurocrine Biosciences, Inc.
Jun 08, 2026, 08:30 ET Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new clinician-reported data in patients with intellectual and developmental disabilities demonstrating meaningful and rapid improvements
More news about: Neurocrine Biosciences, Inc.
Jun 03, 2026, 08:30 ET Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present multiple new analyses of key clinical and patient-reported outcomes up to two years of treatment with
More news about: Neurocrine Biosciences, Inc.
May 26, 2026, 16:01 ET Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
SAN DIEGO, May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences:
More news about: Neurocrine Biosciences, Inc.
May 18, 2026, 16:05 ET Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from a clinician survey highlighting the functional impact experienced by patients with mild tardive dyskinesia
More news about: Neurocrine Biosciences, Inc.
May 18, 2026, 08:46 ET Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the completion of its acquisition of Soleno Therapeutics, Inc., strengthening the company's leadership in endocrinology and rare disease.
More news about: Neurocrine Biosciences, Inc.
May 06, 2026, 08:30 ET Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of the first peer-reviewed expert recommendations to guide glucocorticoid dose reduction in patients with classic congenital
More news about: Neurocrine Biosciences, Inc.
May 05, 2026, 16:01 ET Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
BillionSAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2026.
More news about: Neurocrine Biosciences, Inc.
May 05, 2026, 09:00 ET Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
SAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the Bank of America Health Care Conference 2026 at 11:20 a.m. Pacific Time (2:20 p.m Eastern
More news about: Neurocrine Biosciences, Inc.
May 04, 2026, 08:30 ET Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey revealing the significant impact of tardive dyskinesia (TD) on people's ability to work, go
More news about: Neurocrine Biosciences, Inc.
May 04, 2026, 07:30 ET Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'2118 in adult participants.
More news about: Neurocrine Biosciences, Inc.
May 01, 2026, 16:05 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new two-year data from the Phase 3 CAHtalyst® Pediatric study demonstrating durable androgen control,
More news about: Neurocrine Biosciences, Inc.
Apr 29, 2026, 16:05 ET Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of new peer-reviewed research in
More news about: Neurocrine Biosciences, Inc.
Apr 22, 2026, 16:05 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study demonstrating sustained, substantial
More news about: Neurocrine Biosciences, Inc.
Apr 14, 2026, 16:01 ET Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
SAN DIEGO, April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern
More news about: Neurocrine Biosciences, Inc.
Apr 14, 2026, 08:30 ET Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new real-world evidence demonstrating that adult patients with tardive dyskinesia receiving
More news about: Neurocrine Biosciences, Inc.
Apr 06, 2026, 07:00 ET Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
SAN DIEGO and REDWOOD CITY, Calif., April 6, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Soleno Therapeutics, Inc. (Nasdaq: SLNO) today announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per
More news about: Neurocrine Biosciences, Inc.
Mar 26, 2026, 08:30 ET Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first expert consensus recommendations focused on screening, diagnosis and treatment of tardive dyskinesia among
More news about: Neurocrine Biosciences, Inc.
Mar 17, 2026, 16:05 ET Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer. In his new role, Dr.
More news about: Neurocrine Biosciences, Inc.
Mar 10, 2026, 16:01 ET Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
SAN DIEGO, March 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the Stifel 2026 Virtual CNS Forum at 4:30 PM EST on March 17, 2026.
More news about: Neurocrine Biosciences, Inc.
Mar 06, 2026, 17:00 ET BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)
Neurocrine Bio In. (NASDAQ: NBIX), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective. Committee
More news about: NAIC-BetterInvesting
Feb 24, 2026, 16:01 ET Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:
More news about: Neurocrine Biosciences, Inc.